Trials / Completed
CompletedNCT03136068
Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation
Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation: a Placebo-controlled, Double-blinded Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D\&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D\&E procedure, but doctors want to clarify how digoxin effects D\&E procedure time, if at all.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Digoxin | Trans-abdominal injection |
| DRUG | Placebo | Trans-abdominal injection |
Timeline
- Start date
- 2017-02-23
- Primary completion
- 2018-05-31
- Completion
- 2018-05-31
- First posted
- 2017-05-02
- Last updated
- 2019-10-30
- Results posted
- 2019-10-30
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03136068. Inclusion in this directory is not an endorsement.